ASCENTAGE-B (06855) announced that it has confidentially submitted an F-1 registration statement draft for a proposed initial public offering to the SEC. On December 23, 2024 (Hong Kong time), the China Securities Regulatory Commission (CSRC) published a notice on its website regarding the company’s filing with the CSRC for the proposed initial public offering, confirming the filing content and that the filing application has been completed. On December 27, 2024 (Eastern Time), the company publicly submitted an F-1 registration statement to the SEC regarding the proposed initial public offering representing its ordinary shares in American Depositary Shares (with a par value of $0.0001 per share), which is not yet effective. J.P. Morgan Securities LLC and Citigroup Global Markets Inc. are serving as joint book-running managers and underwriters for the proposed offering.
亚盛医药-B：拟申请在纳斯达克全球精选市场(或纳斯达克)上市美国存托股份
ASCENTAGE-B intends to apply for the listing of American Depositary Shares on the Nasdaq Global Select Market (or Nasdaq).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.